Search results
Results From The WOW.Com Content Network
Sanofi forecasts Beyfortus sales for the fourth quarter to be similar to the third quarter. Price Action: SNY stock is up 2.82% at $53.52 during the premarket session at the last check on Friday.
The French drugmaker forecast 2024 earnings per share would remain stable versus 2023 levels, an improvement on its previous expectation of a low single-digit percentage fall, at constant currency ...
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Paris-based Sanofi (NYSE:SNY) beat analyst estimates in its earnings for Q2. Now, with new drugs coming into the market, SNY stock could be poised for a recovery. This missed Wall Street estimates ...
Sanofi was founded in 15 February 1973 [5] as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly; [6] Labaz developed benziodarone in 1957.
That puts the stock market in a precarious position. Expectations regarding rate cuts could change based on an important economic data point that will be published on Wednesday, Nov. 27.
Before you buy stock in Sanofi, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sanofi wasn’t ...
Here's why tomorrow could be a big day for the stock market. Economic data over the coming months could play a big role in determining how the market performs in the near term and in 2025.